Literature DB >> 17334665

Comparison of interferon-gamma response between tuberculosis and non-tubercular pneumonia.

H-P Wu1, C-C Hua, Y-C Liu, D-Y Chuang.   

Abstract

OBJECTIVE AND
DESIGN: Macrophages aided by interferon-gamma (IFN-gamma) are vital to controlling Mycobacterium tuberculosis (M. tuberculosis) infection. Although numerous studies have compared IFN-gamma response between tubercular patients and healthy controls, no studies have investigated IFN-gamma response in patients with pulmonary tuberculosis and non-tubercular pneumonia. The aim of this work was to examine the difference in IFN-gamma response between patients with tuberculosis and non-tubercular pneumonia.
METHODS: IFN-gamma production was detected based on the difference in supernatants between non-stimulated and stimulated peripheral blood mononuclear cells by phytohemagglutinin in 83 tubercular patients and 47 patients with pneumonia. Presence of a cavity on chest radiography and co-morbidities of pneumoconiosis, bronchiectasis, liver cirrhosis, renal failure on hemodialysis, diabetes mellitus (DM) and lung cancer were recorded for analysis.
RESULTS: Interferon-gamma response, DM and a cavity on chest radiography were independent factors for predicting active pulmonary tuberculosis. Interferon-gamma response was decreased in patients with pulmonary tuberculosis compared with that in patients with non-tubercular pneumonia. Notably, M. tuberculosis infection was the principal factor correlated with IFN-gamma response.
CONCLUSION: The IFN-gamma response was principally affected by M. tuberculosis infection and not by other co-morbidities. Further study is required to identify the mechanism of decreased IFN-gamma production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334665     DOI: 10.1007/s00011-007-6083-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  1 in total

Review 1.  Current issues on molecular and immunological diagnosis of tuberculosis.

Authors:  Sang-Nae Cho
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.